Piperacillin, an new semi-synthetic penicillin in pediatrics

G. Segni, E. Salvaggio, C. Auriti

Research output: Contribution to journalArticlepeer-review


Forty-one hospitalized pediatric patients, age range 0.5 month-12 years (mean 2.5), with various acute and exacerbated chronic infectious pathology (upper RTI 5; lower RTI 28; UTI 2; others 8) were treated with piperacillin by I.M. or I.V. drip, with dosage range 50-400 mg/Kg/die for 4-19 days (mean 9.0). Infecting organisms were isolated from 17 patients. All organisms tested were shown to be susceptible to piperacillin. Clinical cure was achieved in 38 patients (92.7%) and improvement in 3 (7.3%). Eradication of causative organism was achieved in 64.7% of patients, significant reduction in 17.6% and persistence in 17.6%. No relapses occurred. No toxic effects due to piperacillin nor significant changes in blood chemistry were seen even with the higher dosage (400 mg/Kg/die I.V. for 6 days). Only in 2 patients were mild side effects of probable allergic type observed. Piperacillin was generally well tolerated, non-toxic, easy to use and effective especially against Pseudomonas spp. Our results show that piperacillin is a good and safe antibiotic for the treatment of bacterial infections in pediatrics.

Original languageEnglish
Pages (from-to)265-271
Number of pages7
JournalCurrent Therapeutic Research
Issue number2
Publication statusPublished - 1983

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Piperacillin, an new semi-synthetic penicillin in pediatrics'. Together they form a unique fingerprint.

Cite this